Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors

Item

http://www.wikidata.org/entity/Q36540405

description

2016 nî lūn-bûn

@nan

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

name

Factors that predict progressi ...... tor tyrosine kinase inhibitors

@ast

Factors that predict progressi ...... tor tyrosine kinase inhibitors

@en

type

Item

label

Factors that predict progressi ...... tor tyrosine kinase inhibitors

@ast

Factors that predict progressi ...... tor tyrosine kinase inhibitors

@en

prefLabel

Factors that predict progressi ...... tor tyrosine kinase inhibitors

@ast

Factors that predict progressi ...... tor tyrosine kinase inhibitors

@en

P1476

Factors that predict progressi ...... tor tyrosine kinase inhibitors

@en

P2093

Aiqin Gu

http://www.w3.org/2001/XMLSchema#string

Huangping Shi

http://www.w3.org/2001/XMLSchema#string

Huimin Wang

http://www.w3.org/2001/XMLSchema#string

Lili Dong

http://www.w3.org/2001/XMLSchema#string

Liwen Xiong

http://www.w3.org/2001/XMLSchema#string

Liyan Jiang

http://www.w3.org/2001/XMLSchema#string

Shaohua Cui

http://www.w3.org/2001/XMLSchema#string

Tianqing Chu

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Yizhuo Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

68-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2072-1439.2016.01.12

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295813715

http://www.w3.org/2001/XMLSchema#string

P698

26904214

http://www.w3.org/2001/XMLSchema#string

P932

4740173

http://www.w3.org/2001/XMLSchema#string